ALKERMES | Passivo Circulante





Passivo Circulante Alterar Data
AbbVie USD 43.29B 3.9B 2025-12
Acadia Pharmaceuticals USD 356.58M 26.56M 2025-09
ALKERMES USD 474.36M 31.6M 2025-09
Amgen USD 25.49B 3.7B 2025-12
Biogen USD 3.35B 59.4M 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Bristol-Myers Squibb USD 28.14B 608M 2025-09
Coherus Biosciences USD 372.3M 108.67M 2025-09
Eli Lilly USD 35.23B 4.91B 2025-12
Gilead Sciences USD 11.81B 485M 2025-12
Heron Therapeutics USD 89.71M 168.89M 2025-09
Ionis Pharmaceuticals USD 903.46M 6.22M 2025-09
J&J USD 54.13B 3.26B 2025-12
Malin Corporation EUR 1000K 500K 2024-12
Merck USD 28.63B 2.59B 2025-09
Minerva Neurosciences USD 2.67M 143K 2025-09
Nektar Therapeutics USD 66.34M 5.05M 2025-09
Neurocrine Biosciences USD 743.4M 105.4M 2025-12
Otsuka Holdings JPY 749.11B 50.84B 2025-12
Ovoca Bio EUR 2.44M 1.1M 2022-06
Pfizer USD 36.6B 1.13B 2025-09
Regeneron Pharmaceuticals USD 4.37B 56.7M 2025-12
Vertex Pharmaceuticals USD 3.86B 614.1M 2025-12


ALKERMES Passivo Circulante - Valores atuais, dados históricos, previsões, estatísticas, gráficos e calendário econômico - Feb 2026.